Fundraising Fox
/Companies
Sign in

Avro Life Science

YC W18

Waterloo, CA · 8 employees · 17 known investors

Find your way into Avro Life Science

Sign up to see every warm intro you have to Avro Life Science

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Avro Life Science team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Avro Life Sciences develops platform technology for novel drug delivery through passive transdermal administration. The company operates in the biotech sector, focusing on dermatological and systemic therapeutics.

BiotechHealthtechMedical DevicesDrug DeliveryCanadaAmerica / Canada

Founders & leadership· Y Combinator alumni (W18)

SLShak Lakhani
Shak LakhaniFounder
KSKeean Sarani
Keean SaraniCo-FounderKeean Sarani holds a PharmD and is licensed as a registered pharmacist. He is co-founder of Avro Life Science, a biotech company developing transdermal drug delivery platforms for dermatological and systemic therapeutics.

Investors · 17

Embark Ventureslisted by Embark VenturesLos Angeles

How we know: Embark Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

Fifty Yearslisted by Fifty YearsSan Francisco · $250K – $2M

How we know: Fifty Years's portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Garage Capitallisted by Garage CapitalWaterloo

How we know: Garage Capital's portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Heuristic Capital Partnerslisted by Heuristic Capital PartnersSanta Clara

How we know: open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

Jude Gomilalisted by Jude GomilaLynnwood

How we know: Jude Gomila's portfolio page · Not right? Tell us

UpHonest Capitallisted by UpHonest CapitalSilicon Valley · $50K – $1M

How we know: the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Waterloo Accelerator Centrelisted by Waterloo Accelerator CentreWaterloo
Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Buckley Ventures Management Company LlcreportedNew York · $300K

How we know: Y Combinator's founder network · Not right? Tell us

Cannonball CapitalreportedMunich

How we know: Y Combinator's founder network · Not right? Tell us

For Good Venturesreported

How we know: Y Combinator's founder network · open dataset · 5k.vc investor directory · Not right? Tell us

MicroVenturesreportedAustin

How we know: Y Combinator's founder network · Not right? Tell us

ScienceVestreportedNew York · $125K

How we know: Y Combinator's founder network · Not right? Tell us

Selvedge VenturereportedLondon

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Susa VenturesreportedSan Francisco · $1M – $5M

How we know: Y Combinator's founder network · Not right? Tell us

Tamar CapitalreportedSan Francisco

How we know: Y Combinator's founder network · Not right? Tell us

Founder mafia

2 people who came through Avro Life Science went on to found or lead other companies.

Alasdair ThongInvestor/AdvisorFounded Ada Ventures +1Aamir HuddaInvestor RelationsFounded Attain

Related companies · 5

NanograbNanograb develops gene therapy delivery systems using artificial intelligence to identify peptide-nanoparticle combinations that transport genetic medicines to targeted cells and tissues.
ConvexiaConvexia provides AI-powered drug discovery and evaluation software that scans global sources for overlooked drug assets and runs deep in silico simulations across 50+ models to assess binding, toxicity, pharmacokinetics, and immunogenicity. The platform combines AI agents with expert human review to accelerate drug asset evaluation for biotech companies, pharma firms, and venture investors.
Intact TherapeuticsIntact Therapeutics develops next-generation biopharmaceutical therapies for gastrointestinal diseases to address unmet clinical needs. The company is clinical-stage and focused on improving patient outcomes through innovative medicines.
KeylikaKeylika develops a platform synthesis technology for mixed ligand metal complexes to generate organometallic drugs for treating therapeutic conditions including hematology, pain, inflammation, metabolic disorders, infectious diseases, and oncology. The company combines drug development with drug delivery technologies, customizing molecular structure and formulation to optimize clinical outcomes for women, children, elderly, and patients with specific diseases.
Sixfold BioscienceSixfold develops RNA delivery technology for the biotech industry. The company was founded by an oncologist and plant scientist and focuses on advancing RNA-based therapeutic approaches through proprietary delivery methods.

Companies working in the same space as Avro Life Science.

Legal entities · 1

corporate structure
Avro Life Science, Inc.

Frequently asked questions

What does Avro Life Science do?
Avro Life Sciences develops platform technology for novel drug delivery through passive transdermal administration. The company operates in the biotech sector, focusing on dermatological and systemic therapeutics.
Who founded Avro Life Science?
Avro Life Science was founded by Shak Lakhani, Keean Sarani.
Who are Avro Life Science's investors?
Avro Life Science's investors include Creative Destruction Lab (CDL), Embark Ventures, Fifty Years, Garage Capital, Heuristic Capital Partners, Jude Gomila, UpHonest Capital, Waterloo Accelerator Centre and 9 more.
Where is Avro Life Science headquartered?
Avro Life Science is headquartered in Waterloo, CA.